Ignite Creation Date:
2025-12-25 @ 3:23 AM
Ignite Modification Date:
2026-02-23 @ 12:20 PM
Study NCT ID:
NCT06261905
Status:
COMPLETED
Last Update Posted:
2025-11-14
First Post:
2024-02-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System
Sponsor:
Yale University
Organization:
Study Overview
Official Title:
Exploration of Baseline Alterations on the Dopamine D2/D3 Receptor System and the Effects of Vitamin D in Opioid Use Disorder: an [11C]-PHNO Study
Status:
COMPLETED
Status Verified Date:
2025-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The research team is investigating Opioid Use Disorder (OUD), a disorder characterized by dysregulated dopaminergic tone, to evaluate the mechanisms of adjunctive treatment with calcitriol. The investigators will recruit 12 subjects with OUD and 12 healthy subjects to participate in a double-blind, randomized study design where subjects will complete up to 2 Positron Emission Tomography (PET) scans using \[11C\]-PHNO. The investigators will compare subjects in differences between their own study days and in differences between healthy control subjects and subjects with OUD.
Detailed Description:
Previous research has indicated that Dopamine (DA) may play a role in withdrawal and dependence in Opioid Use Disorder (OUD). The present study will investigate dopamine receptor availability in 12 subjects with OUD compared with 12 HC subjects using \[11C\](+)-PHNO and the impact of calcitriol on these receptors.
Research has indicated that a common feature in substance use disorders (SUD) is a hypo-dopaminergic state. Further, preclinical and observational research has pointed to a possible benefit of calcitriol in individuals who have OUD and our research group has previously shown the potential benefits of calcitriol on addressing this hypo-dopaminergic state. If successful, the results of this research study may improve the standard treatment for OUD through calcitriol supplementation.
Specifically, the present study seeks to address the following aims:
Specific Aim 1: As part of a between-subject study design, to determine whether acute calcitriol (vs. placebo) administration is associated with greater dopamine (DA) release in the caudate, putamen, ventral striatum (VST), and substantia nigra / ventral tegmental area (SN/VTA) of subjects with OUD compared to healthy control subjects (HCs).
Specific Aim 2: As part of a within-subject, two-day study design, to determine whether acute calcitriol (vs. placebo) administration is associated with greater dopamine (DA) release in the caudate, putamen, ventral striatum (VST), and substantia nigra / ventral tegmental area (SN/VTA) of subjects with OUD.
Specific Aim 3: To determine whether acute calcitriol (vs. placebo) administration is associated with higher spontaneous eyeblink rate, a non-PET indicator of higher dopamine activity, among subjects with OUD.
Specific Aim 4: To determine whether acute calcitriol (vs. placebo) administration is associated with better performance on neurocognitive measures (e.g., the Continuous Performance Task or CPT-IP and the Probabilistic Reversal Learning Task or PRLT) among subjects with OUD.
Research has indicated that a common feature in substance use disorders (SUD) is a hypo-dopaminergic state. Further, preclinical and observational research has pointed to a possible benefit of calcitriol in individuals who have OUD and our research group has previously shown the potential benefits of calcitriol on addressing this hypo-dopaminergic state. If successful, the results of this research study may improve the standard treatment for OUD through calcitriol supplementation.
Specifically, the present study seeks to address the following aims:
Specific Aim 1: As part of a between-subject study design, to determine whether acute calcitriol (vs. placebo) administration is associated with greater dopamine (DA) release in the caudate, putamen, ventral striatum (VST), and substantia nigra / ventral tegmental area (SN/VTA) of subjects with OUD compared to healthy control subjects (HCs).
Specific Aim 2: As part of a within-subject, two-day study design, to determine whether acute calcitriol (vs. placebo) administration is associated with greater dopamine (DA) release in the caudate, putamen, ventral striatum (VST), and substantia nigra / ventral tegmental area (SN/VTA) of subjects with OUD.
Specific Aim 3: To determine whether acute calcitriol (vs. placebo) administration is associated with higher spontaneous eyeblink rate, a non-PET indicator of higher dopamine activity, among subjects with OUD.
Specific Aim 4: To determine whether acute calcitriol (vs. placebo) administration is associated with better performance on neurocognitive measures (e.g., the Continuous Performance Task or CPT-IP and the Probabilistic Reversal Learning Task or PRLT) among subjects with OUD.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 000 | OTHER | CTGTY | View |